Suramin as an archetypical compound in the development of growth factor antagonists for inhibition of genitourinary tumors
- 1 January 1992
- book chapter
- Published by Springer Nature
- Vol. 59, 131-151
- https://doi.org/10.1007/978-1-4615-3502-7_12
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Synergistic Activity of Suramin With Tumor Necrosis Factor and Doxorubicin on Human Prostate Cancer Cell LinesJNCI Journal of the National Cancer Institute, 1990
- Suramin-induced differentiation of the human colic adenocarcinoma cell clone HT29-D4 in serum-free mediumExperimental Cell Research, 1990
- Suramin for prostatic cancer: A phase I/II study in advanced extensively pretreated diseaseEuropean Journal of Cancer and Clinical Oncology, 1990
- Antiproliferative effects of suramin on androgen responsive tumour cellsEuropean Journal of Cancer and Clinical Oncology, 1990
- Suramin, an anti‐cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2AFEBS Letters, 1989
- Autocrine secretion of a colorectum‐derived growth factor by HT‐29 human colon carcinoma cell lineInternational Journal of Cancer, 1988
- Production and utilization of growth factors related to fibroblast growth factor by embryonal carcinoma cells and their differentiated cellsDevelopmental Biology, 1988
- Inhibition of vacuolar H+‐ATPases by fusidic acid and suraminFEBS Letters, 1988
- Analysis of growth factors in renal cell carcinomaBiochemical and Biophysical Research Communications, 1988
- Prostatic growth factor: purification and structural relationship to basic fibroblast growth factorBiochemistry, 1987